All questionsClinical trials: Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer8 questions · 1 sourceClinical trialsWho was eligible for the KEYTRUDA KEYNOTE-522 trial?“1,174 patients with newly diagnosed, previously untreated high-risk early-stage TNBC were evaluated in a randomized, multicenter, double-blind, placebo-controlled trial Patient Eligibility Key Inclusion Criteria Patients with newly diagnosed, previously untreated high-risk early-stage TNBC Patients were enrolled regardless of tumor PD-L1 expression Tumor size >1 cm but ≤2 cm in diameter with nodal involvement or tumor size >2 cm in diameter regardless of nodal involvement Key Exclusion Criteria Patients with active autoimmune disease that required systemic therapy within 2 years of treatment Patients with a medical condition that required immunosuppression” (opens the source at this quote in a new tab)CopyFlagWhat chemotherapy was given with KEYTRUDA in KEYNOTE-522?“Study Arms KEYTRUDA (n=784) Neoadjuvant Regimen (cycles 1–4) KEYTRUDA 200 mg Q3W on day 1 Carboplatin (AUC 5 mg/mL/min Q3W on day 1 OR AUC 1.5 mg/mL/min (weekly) on days 1, 8, and 15) Paclitaxel (80 mg/m2 on days 1, 8, and 15) Neoadjuvant Regimen (cycles 5–8) KEYTRUDA 200 mg Q3W on day 1 Doxorubicin (60 mg/m2 Q3W) on day 1 OR Epirubicin (90 mg/m2 Q3W) on day 1 Cyclophosphamide (600 mg/m2 Q3W) on day 1 Surgery Adjuvant Regimen (9 cycles) KEYTRUDA 200 mg Q3W on day 1 Placebo (n=390) Neoadjuvant Regimen (cycles 1–4) Placebo Q3W on day 1 Carboplatin (AUC 5 mg/mL/min Q3W on day 1 OR AUC 1.5 mg/mL/min (weekly) on days 1, 8, and 15) Paclitaxel (80 mg/m2 on days 1, 8, and 15) Neoadjuvant Regimen (cycles 5–8) Placebo Q3W on day 1 Doxorubicin (60 mg/m2 Q3W) on day 1 OR Epirubicin (90 mg/m2 Q3W) on day 1 Cyclophosphamide (600 mg/m2 Q3W) on day 1 Surgery Adjuvant Regimen (9 cycles) Placebo Q3W on day 1” (opens the source at this quote in a new tab)CopyFlag“All study medications were administered intravenously.” (opens the source at this quote in a new tab)CopyFlagDoes the KEYTRUDA benefit come from treatment before or after surgery (KEYNOTE-522)?“The trial was not designed to isolate the effect of KEYTRUDA in each phase (neoadjuvant or adjuvant) of treatment.” (opens the source at this quote in a new tab)CopyFlagWhat were baseline characteristics in the KEYTRUDA KEYNOTE-522 trial?“Baseline Characteristics (N=1,174) Median age, years (range): 49 (22–80) Aged ≥65 years: 11% Female: 99.9% Race White: 64% Asian: 20% Black: 4.5% American Indian or Alaska Native: 1.8% ECOG PS 0: 87% 1: 13% Menopausal status Pre-menopausal: 56% Post-menopausal: 44% Primary tumor classification T1: 7% T2: 68% T3: 19% T4: 7% Nodal involvement N0: 49% N1: 40% N2: 11% N3: 0.2% Overall disease stage II: 75% III: 25%” (opens the source at this quote in a new tab)CopyFlagStudy resultsHow often did KEYTRUDA plus chemotherapy leave no invasive cancer at surgery (KEYNOTE-522)?“pCR was defined as absence of invasive cancer in the breast and lymph nodes (ypT0/Tis ypN0) and was assessed by the blinded local pathologist at the time of definitive surgery.” (opens the source at this quote in a new tab)CopyFlag“Pathological Complete Response (pCR) Rate pCR With KEYTRUDA + Chemotherapyc vs Placebo + Chemotherapyc in the Neoadjuvant Setting pCR Rate (ypT0/Tis ypN0)d pCR 63.0% (95% CI, 59.5–66.4) (n/N=494/784) KEYTRUDA + chemotherapyc vs pCR 55.6% (95% CI, 50.6–60.6) (n/N=217/390) Placebo + chemotherapyc Estimated treatment difference: ~7.5% (95% CI, 1.6–13.4)e,f with KEYTRUDA + chemotherapyc vs placebo + chemotherapyc c. Carboplatin/paclitaxel followed by AC or EC. d. Based on the entire intention-to-treat population N=1,174 patients. e. Based on a prespecified pCR interim analysis in patients (n=602), the pCR rate difference was statistically significant (P=0.00055 compared to a significance level of 0.003). f. Based on Miettinen and Nurminen method stratified by nodal status, tumor size, and choice of carboplatin. CI = confidence interval; AC = doxorubicin + cyclophosphamide; EC = epirubicin + cyclophosphamide.” (opens the source at this quote in a new tab)CopyFlagWhat was KEYTRUDA event-free survival in KEYNOTE-522?“Superior EFS With KEYTRUDA + Chemotherapyg/KEYTRUDA vs Placebo + Chemotherapyg/Placebo at IA4” (opens the source at this quote in a new tab)CopyFlag“37% reduction in the risk of an EFS eventk with KEYTRUDA + chemotherapyg/KEYTRUDA vs placebo + chemotherapyg/placebo (HRh=0.63; 95% CI, 0.48–0.82; Pi,j=0.00031) The number of patients with an event was 123/784 (16%) with KEYTRUDA + chemotherapyg/KEYTRUDA vs 93/390 (24%) with placebo + chemotherapyg/placebo g. Carboplatin/paclitaxel followed by AC or EC. h. HR based on stratified Cox regression model. i. P value based on a prespecified EFS interim analysis (compared to a significance level of 0.0052). j. P value based on log-rank test stratified by nodal status, tumor size, and choice of carboplatin. k. EFS was defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, or death due to any cause. HR = hazard ratio. IA4 = fourth interim analysis.” (opens the source at this quote in a new tab)CopyFlagDoes KEYTRUDA with chemotherapy lower the risk of death in early-stage TNBC (KEYNOTE-522)?“Superior Overall Survival (OS) With KEYTRUDA + Chemotherapyl/KEYTRUDA vs Placebo + Chemotherapyl/Placebo at IA73” (opens the source at this quote in a new tab)CopyFlag“34% reduction in the risk of death with KEYTRUDA + chemotherapyl/KEYTRUDA vs placebo + chemotherapyl/placebo (HRm=0.66; 95% CI, 0.50–0.87; Pn,o=0.00150) The number of patients with an event was 115/784 (15%) with KEYTRUDA + chemotherapyl/KEYTRUDA vs 85/390 (22%) with placebo + chemotherapyl/placebo l. Carboplatin/paclitaxel followed by AC or EC. m. Based on stratified Cox regression model. n. Based on log-rank test stratified by nodal status, tumor size, and choice of carboplatin. o. Based on prespecified OS interim analysis (compared to a significance level of 0.0050). IA7 = seventh interim analysis.” (opens the source at this quote in a new tab)CopyFlagInterpreting study resultsWhat are the limitations of KEYTRUDA KEYNOTE-522 survival subgroup results?“LIMITATIONS: KEYNOTE-522 was not powered to detect differences in the treatment effect in these subgroups, and no statistical testing was planned for this analysis; therefore, no conclusions can be drawn. Results from exploratory subgroup analyses should be interpreted with caution because of the modest patient numbers and potential imbalances in baseline characteristics within the subgroups.” (opens the source at this quote in a new tab)CopyFlag